Halozyme posts record Q2 2026, raises full-year guidance on royalty growth
Five new ENHANZE and Hypercon collaborations signed through July, including deals with Vertex, GSK, Incyte and Oruka, push revenue and EBITDA guidance higher.
Halozyme Therapeutics reported second quarter 2026 results on August 6, 2026 and raised its full-year financial guidance. The company said it expanded its royalty revenue opportunity by signing five new ENHANZE and Hypercon collaborations through July, including agreements with Vertex, Oruka, GSK, Incyte and an undisclosed partner that is the first to license ENHANZE for a nucleic acid therapeutic.1
On the partner pipeline, in July 2026 Halozyme and Incyte entered into a global collaboration and license agreement to evaluate additional subcutaneous formulations of INCA033989, a mutant calreticulin-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms, with Incyte holding an option to nominate up to two additional targets.1 In the third quarter of 2026, the ongoing ARGX-119 adimanebart program was expanded to include a Phase 1 SC bioavailability study with ENHANZE.1
On regulatory and clinical fronts, Janssen announced in May 2026 pivotal results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj delivered durable responses in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemotherapy, and submitted a supplemental Biologics License Application to the FDA.1 Also in May 2026, argenx announced FDA approval of a sBLA for VYVGART Hytrulo with ENHANZE for generalized myasthenia gravis across all serotypes.1 Takeda announced positive topline results from its pivotal Phase 2/3 trial of TAK-881 with ENHANZE in Primary Immunodeficiency Disease.1
On capital, the company repurchased 4.8 million shares for $332.8 million at an average price of $69.30 per share during the second quarter1, and cash, cash equivalents, restricted cash and marketable securities totaled $231.9 million on June 30, 2026, up from $145.4 million at year-end 2025, driven primarily by cash generated from operations.1
For 2026, Halozyme now expects total revenue of $1.835 billion to $1.910 billion, royalty revenue of $1.220 billion to $1.245 billion, adjusted EBITDA of $1.225 billion to $1.280 billion, and non-GAAP diluted EPS of $8.65 to $9.00.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.